Alpha 1-Adrenoceptor Blocker May Improve Not Only Voiding But Also Storage Lower Urinary Tract Symptoms Caused by 125I Brachytherapy for Prostate Cancer
Table 1
Patient characteristics.
Characteristics
Tamsulosin ()
Silodosin ()
Naftopidil ()
value
Age (y)
Mean
68.9
66.4
68.7
NS
Range
58–82
54–80
54–77
PSA at biopsy (ng/mL)
Mean
12.0
11.3
8.2
NS
Range
3.1–61.9
3.1–88.9
3.0–36.4
Gleason sum
Mean
6.7*
7
7.3*
0.05*
Range
3–9
6–9
6–9
Prostate volume at BT (cc)
Mean
28.4
27.4
31
NS
Range
13.9–54.5
14.2–46.1
18.2–48.6
IPSS before treatment
Mean
9.9
9.4
8.8
NS
Range
1–32
0–29
0–25
Neoadjuvant HT
Yes
22
9
14
No
27
23
21
Number of seeds
Mean
67.6
69.4
72.9
NS
Range
30–95
45–95
55–95
EBRT
Yes
26
23
22
No
23
9
13
Risk category
Low risk
15
7
2
Intermediate risk
14
15
20
High risk
20
10
13
PSA: prostatic specific antigen; BT: brachytherapy; IPSS: International Prostate Symptoms Score; HT: hor-mone therapy; EBRT: external beam radiation threrapy.
*Tamsulosin versus naftopidil; 6.7 versus 7.3, .
